November 18, 2026
Health news, explained with evidence
LIVE

Study Highlights Significant Insurance Delays and Denials for Pediatric Biologic Prescriptions

🧠 AI Analysis 2 min read 👁 7

New research presented at the American College of Allergy, Asthma and Immunology annual meeting reveals that nearly 40% of pediatric biologic prescriptions needing prior authorization face denial.

Study Highlights Significant Insurance Delays and Denials for Pediatric Biologic Prescriptions🧠AI Analysis

Photo: Medical Xpress

Key points

  • Nearly 40% of pediatric biologic prescriptions needing prior authorization were denied.
  • The average wait time from prescription to final approval reached over 32 days.
  • Omalizumab and dupilumab accounted for the vast majority of analyzed prescriptions.

A recent retrospective study presented at the annual meeting of the American College of Allergy, Asthma and Immunology demonstrates that young patients experience substantial waiting periods and high denial rates when prescribed biologic treatments for atopic conditions. Led by Dr. Mark Holland and colleagues at Children's Mercy Hospital in Kansas City, Missouri, the investigation reviewed charts of pediatric patients with a median age of 11.4 years who were prescribed medications such as omalizumab, dupilumab, mepolizumab, benralizumab, and tezepelumab between 2018 and 2026.

Out of 326 evaluated prescriptions, the data showed that 39.3% of requests requiring prior authorization were ultimately rejected by insurance payers. The primary justifications cited for these denials included failing to meet specific insurance criteria and being required to try prerequisite therapies first. Furthermore, for the prescriptions that did successfully secure clearance, patients faced an average waiting period of 32.6.5 days from the initial doctor's order to final approval.

What to know: While the findings highlight potential administrative barriers in pediatric allergy care, the study is observational and reflects institutional review practices that may vary across regions and insurance providers. Readers should consult qualified healthcare professionals regarding personal medical decisions and treatment plans.

"Children shouldn't have to wait weeks for care their allergist knows they need immediately," noted co-author Dr. Aarti Pandya.

Source Medical Xpress — medicalxpress.com/news/2026-11-acaai-considerable-delay-rx-children.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.